Trial Profile
A study evaluating efficacy of Dapagliflozin-low dose Pioglitazone combination for treatment of nonalcoholic fatty liver disease compared to Dapagliflozin-Glimepiride combination.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Jul 2017
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Pioglitazone (Primary) ; Glimepiride
- Indications Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 19 Jul 2017 New trial record
- 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association